US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Pergamum announces that the first patient has been dosed with a potential new treatment for hard-to-heal wounds

STOCKHOLM – September 11, 2012. Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of its drug candidate LL-37 for the treatment of patients with hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of Pergamum."Non-healing wounds are a huge burden for the individual patient and for the health care system. Today, there are an estimated 15 million patients with chronic wounds globally, and virtually no medical progress has been made in this area over the last few decades", said Jonas Ekblom, CEO of Pergamum AB. "This clinical trial

Pergamum reports top line Phase II-data from the clinical trial for prevention of post-surgical adhesions

SWEDEN, STOCKHOLM – July 10, 2012. Pergamum AB, a Karolinska Development portfolio company, today announced top-line results from the randomized first time in patient Phase II trial of PXL-01 for prevention of post-surgical adhesions. The study showed that the drug was safe and well tolerated. The primary end point of the study was not met. However, the data suggests that PXL-01 may improve the postoperative outcome regarding the hand mobility after surgery.Top-line results from the Phase II trial on subjects that have undergone tendon repair surgery in the hand have now been analyzed.

Margit Mahlapuu appointed as CSO of Pergamum AB

SWEDEN, STOCKHOLM – 2 May, 2012. Pergamum AB today announced that Dr. Margit Mahlapuu was appointed as the company’s Chief Scientific Officer (CSO).Pergamum AB was formed in 2009 with the objective of synergetically aggregating a number of programs in the field of locally delivered biopharmaceuticals. The company has operations in several locations in Sweden. The company announced today that Dr. Margit Mahlapuu will take on the role as Chief Scientific Officer in Pergamum. ”I would like to congratulate and welcome Dr. Margit Mahlapuu in her new role as Chief Scientific Officer. She

Pergamum completes patient recruitment to the Phase II clinical trial for prevention of post-surgical adhesions

SWEDEN, STOCKHOLM - February 10, 2012. Pergamum AB announced today that the last patient has been dosed in a randomized Phase II trial of PXL01 for prevention of post-surgical adhesions. Karolinska Development AB is the majority owner of Pergamum.In total, 138 patients undergoing hand surgery have been included in Pergamum's placebo controlled, multi-center trial that has been conducted in Sweden, Denmark and Germany. The trial evaluates the safety and effectiveness of the novel therapeutic peptide PXL01 to improve mobility and function of the hand after surgery. Many patients undergoing

Pergamum initiates Phase II trial with DPK-060 in outer ear infections

STOCKHOLM, SWEDEN - January 16, 2012. Pergamum AB today announced that the first patient has been dosed in a randomized Phase II study of DPK-060 for the treatment of patients with external otitis (swimmers ear)."Every year more than 10 million people world-wide seek medical care for treatment of infections in the outer ear. There is a significant medical need to avoid rapidly increasing global prevalence of antibiotics resistance that limits the therapeutic value of conventional products, and we think that we can meet this need with DPK-060", says Jonas Ekblom, CEO of Pergamum Pergamum'

Torbjörn Bjerke appointed Chairman of Pergamum AB

Torbjörn Bjerke, Chief Executive Officer, Karolinska Development AB (publ), was appointed Chairman of the Board of Directors following the Annual Shareholders’ Meeting in Pergamum AB on June 22, 2011."Several of Pergamum's development initiatives have the potential of changing future medical practice in the area of dermatology and wound healing. The company is an important part of the Karolinska Development portfolio and I look forward to working with the Board and management team to take the company and its three main development programs forward", says Torbjörn Bjerke. "Pergamum has a

Corrado Sablone joins Pergamum AB as Chief Financial Officer

Stockholm, May 30, 2011. Pergamum, a Swedish biotechnology company with focus on the development of new treatments for wounds and skin infections, today announced the hire of Corrado Sablone as Chief Financial Officer. Mr Sablone joins Pergamum from Coca Cola Enterprises Sverige AB, where he has been the Commercial Controlling Manager since 2006. Prior to Coca Cola, Corrado Sablone has served as business controller in several companies, including public international corporations such as Tetra Pak and Tradimus.”Corrado brings outstanding financial and management expertise to our executive

Pergamum appoints Jan Nilsson as Chief Marketing Officer

Stockholm, May 13, 2011. Pergamum has appointed Jan Nilsson as Chief Marketing Officer and as Managing Director of the LL-37 program – Pergamum’s program for wound healing in chronic leg ulcers. Jan Nilsson has previously held a number of executive leadership positions within international life science companies. Also, he has worked as an executive consultant and advisor for a number of smaller biotechs."Jan Nilsson will provide significant leadership capabilities to Pergamum. In his role as Chief Marketing Officer, he will strengthen our ability to design our development programs based on

Pergamum implements offset share issue worth SEK 120m

STOCKHOLM - May 12, 2011. Pergamum AB, Karolinska Development's portfolio company within wound- and skin infections, has conducted an offset share issue, amounting to a total value of SEK 119.6m (EUR 13.3m). Of the total amount, SEK 77.6m (EUR 8.7m) comes from Karolinska Development, thereby increasing its ownership from 60 to 61 percent.Pergamum was founded in 2009 in order to create a strong company in the development of new, effective treatments for wound- and skin infections. The company currently has two Phase II programs, DPK-060 in skin- and soft tissue infections and PXL01 for the

Pergamum to extend Phase II clinical trial for prevention of post-surgical adhesions

Stockholm, Sweden - February 14, 2011. Pergamum AB - the Karolinska Development dermatology and wound healing company - has received approval from the German Regulatory Authority and the Independent Ethics Committee to begin a Phase II clinical trial in Germany. The trial will monitor efficacy and safety of PXL01 for the prevention of post-surgical adhesions in patients undergoing hand surgery."At this juncture, we feel very confident about the program and the strength of our approach to investigate the effects of PXL01. The trial is currently ongoing at several sites in Sweden and in

Jonas Ekblom appointed new Pergamum CEO

STOCKHOLM - October 28, 2010. Jonas Ekblom has been appointed as new Chief Executive Officer of Pergamum AB, the dermatology and wound healing company in the Karolinska Development portfolio, from November 1, 2010." We are delighted to have attracted Jonas Ekblom, who with his vast experience from pharmaceutical development will be able to contribute to a continuous strong development of Pergamum and its programs. Pergamum is a unique biotech company dedicated to the development of new, innovative treatments within dermatology and wound healing. Currently, we have a number of promising pre-

Pergamum appoints Jørgen Thorball as New Chairman of the Board

STOCKHOLM, Sweden - November 30, 2009. Karolinska Development AB and Pergamum AB announced today the appointment of Jørgen Thorball as Chairman of the Board of Directors of Pergamum AB, as of November 25, 2009. Dr. Thorball has extensive experience including the successful development and commercialization of new products within the pharmaceutical and healthcare industries. The appointment of Dr. Thorball brings a considerable experience in successful corporate deals and M&A transaction from the international pharmaceutical industry, which will significantly strengthen Pergamum's efforts in

Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies

STOCKHOLM - September 10, 2009. Pergamum AB has announced its formation; Pergamum will commercialize the Karolinska Development dermatology and wound healing interests, and create a broad-based therapeutic company in its focus areas.The Pergamum product pipeline consists of five development projects, three of which are undergoing clinical trials. Indications covered within the portfolio include improved wound healing and reduced scar formation, healing hard-to-heal-wounds, the prevention of bacterial and fungal infections, atopic dermatitis and infected wounds and burns.Pergamum CEO

There are no items matching the current filter
There are no more items matching the current filter
Back to top